Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
Status:
NOT_YET_RECRUITING
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides difficile infections (rCDI). The aim of this trial is:
1\) For first episodes and first recurrences of CDI, to test whether a vancomycin P-T is non-inferior to 10-days of fidaxomicin for the prevention of rCDI at 56 days
Phase:
PHASE3
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre